StreetAlpha.app
Home › Stocks › BNTC

Benitec Biopharma Inc. (BNTC)

$8.15
▼ −4.57%
LAST CLOSE · NOV 17

Benitec develops gene therapies for rare genetic diseases, led by a treatment candidate for oculopharyngeal muscular dystrophy. It last closed at $8.15 on Nov 17, down 4.57% on the day. BNTC reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 3 analysts is $17.42 (+113.8% from the last close), with a high of $20.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is BNTC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$49.5M
EPS (diluted)
−$1.02
Valuation
Market cap
$294.4M
36.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$176.4M
At Sep 30
Shareholder equity
$169.6M
Shares outstanding
36.1M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $73K$73KFY2022FY2023: $75K$75KFY2023FY2024: $0$0FY2024

From BNTC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
-$0.31
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on BNTC in the past 90 days
Average 12-month target
$17.42
▲ 113.8% upside

Based on 3 analysts who set a price target on BNTC in the past 90 days. The average target is $17.42, with a high of $20.00 and a low of $14.00, compared with the last close of $8.15.

Low $14.00Avg $17.42High $20.00
Blue marker: last close $8.15
Highest target$20.00
Average target$17.42
Lowest target$14.00
Latest rating changes
Leerink PartnersMaintained
Nov 16Buy$18.27
WedbushTarget raised
Nov 16Buy$17 → $20
Raymond JamesInitiated
Oct 23Buy$14
WedbushTarget raised
Sep 15Buy$16 → $17
WedbushInitiated
Jul 28Buy$16
DateFirmActionRatingPrice target
Nov 16Leerink PartnersMaintainedBuy$18.27
Nov 16WedbushTarget raisedBuy$17 → $20
Oct 23Raymond JamesInitiatedBuy$14
Sep 15WedbushTarget raisedBuy$16 → $17
Jul 28WedbushInitiatedBuy$16
Loading…

Technical Analysis

BNTC · as of the Nov 17 close · updated after every close
Downtrend

The stock is 9% below its 20 day and 17% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the swing low (Oct 19) at $8.00, and the nearest resistance the Pivot at $8.18.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.3%/day
Key levels
$14.3952 week high+76.6%
$11.35200 day average+39.3%
$11.09100 day average+36.1%
$9.5050 day average+16.6%
$9.11Swing high (Oct 29)+11.8%
$8.8720 day average+8.8%
$8.37Pivot R1+2.7%
$8.18Pivot+0.4%
$8.15Last close
$8.00Swing low (Oct 19)−1.8%
$7.97Pivot S1−2.2%
$7.8952 week low−3.2%
Indicators
RSI (14)39.87Weak, oversold below 30Neutral
MACD-0.16Below its signal lineBearish
Stochastic28.0Middle of its rangeNeutral
ADX (14)21.1Weak trend
Williams %R-93.2Oversold below −80, overbought above −20Oversold
CCI (20)-149.6Oversold below −100, overbought above 100Oversold
Rate of change−3.0%Change over 10 sessionsBearish
ATR (14)$0.68Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BNTC

What happened before

See how BNTC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BNTC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BNTC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in BNTC in the last 90 days.

Loading…

See today’s whale options flow across the market →

BNTC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲48 buying vs 32 selling
  • ▼Held by funds -2.9 pts
  • ▲Funds holding +4
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9187+4.6%
In funds' top 1012−50.0%
Held by funds93.1%96.0%−2.9 pts
New / increased15 / 3311 / 36+2.1%
Reduced / sold out21 / 1122 / 100.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BNTC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTC is in one of them and how their past BNTC trades turned out.

BNTC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BNTC in an article yet. Here's the latest on the wider market.

About Benitec Biopharma

Benitec is a biotechnology company in Hayward, California, that develops genetic medicines for rare diseases. Its lead product candidate, BB-301, is a gene therapy being tested for oculopharyngeal muscular dystrophy, a degenerative muscle disorder that affects swallowing, eyelids and limbs. The company's approach uses viral vectors to deliver genetic material that silences a harmful gene while replacing it with a working copy. Its intended users are patients with this condition, and it may work with larger drug companies on some programs.

Headquarters
Hayward, CA